Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)

October 21, 2026

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026

Performance

52-Week Range 11.9% below 52-week high

37.45

17.5452W Low 42.5052W High

1 Week 2.7% below 1-week high

33.231W Low 38.491W High

Roivant Sciences Ltd. - Common Shares (ROIV) traded between $17.54 and $42.50 over the past 52 weeks and last traded at $37.45, 11.9% below its 52-week high. Over the past week it ranged between $33.23 and $38.49.

Past 12 Months

+10.0%

-3.9%

+7.3%

+28.5%

+70.8%

+109.6%

1W +$3.41

1M -$1.54

3M +$2.54

6M +$8.30

YTD +$15.52

1Y +$19.58

ROIV was +109.6% over the past year, +28.5% over six months, +70.8% year to date, +10.0% in the last week.

12 Months vs Market

ROIV

+109.6%

DIA

+12.5%

SPY

+13.8%

QQQ

+15.2%

IWM

+12.0%

Over the past 12 months ROIV returned +109.6% versus DIA (Dow) +12.5%, SPY (S&P 500) +13.8%, QQQ (Nasdaq 100) +15.2% and IWM (Russell 2000) +12.0%.

Volume & Liquidity 1.85× 3-mo avg

Today 13,451,961 3-mo avg 7.3M

7.3M

6.2M

7.3M

6.6M

YTD

6.4M

6.7M

ROIV most recently traded 13,451,961 shares against a 3-month average daily volume of 7.3M.

More News

October 21, 2026

Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months ↗

September 28, 2026

Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

September 23, 2026

Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study

There are notable gap-ups and gap-downs in today's session. ↗

September 08, 2026

Via Chartmill

September 08, 2026

Pulmovant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study

September 08, 2026

From Pulmovant, Inc.

Pulmovant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026

September 06, 2026

From Pulmovant, Inc.

Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call

September 06, 2026

Roivant Sciences Wins FDA Approval for LISRAYA in Dermatomyositis, Launches Immediately ↗

August 28, 2026

Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.

August 27, 2026

Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.

August 27, 2026

JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis

August 26, 2026

Roivant Sciences Q1 Earnings Call Highlights ↗

August 07, 2026

Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update

August 06, 2026

Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS)

August 06, 2026

Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026

July 23, 2026

Could Roivant Sciences Be a Multibagger Stock Over the Next 5 Years? ↗

July 07, 2026

Roivant (ROIV) Q4 2025 Earnings Transcript ↗

May 20, 2026

Roivant Sciences Q4 Earnings Call Highlights ↗

May 20, 2026

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update

Stay updated with the stocks that are on the move in today's pre-market session. ↗

May 20, 2026

Via Chartmill

May 20, 2026

Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval ↗

May 18, 2026

Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy? ↗

May 18, 2026